HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder.

Abstract
Successful management of transitional-cell carcinoma of the urinary bladder is greatly dependent upon regular surveillance and early detection of persistent or recurrent carcinoma. The development of a highly sensitive urinary test for the detection of transitional-cell carcinoma of the bladder could have a dramatic impact on our ability to diagnose and monitor bladder cancer patients as well as influence the treatment outcome. The urinary level of the nuclear matrix protein, NMP22, has been found to be elevated in patients with urothelial malignancy. This has prompted the development of an immunoassay to quantitate urinary NMP22 and use it as a cancer-specific marker. We provide a summary of the studies completed with the immunoassay for urinary NMP22 as an indicator for the presence of transitional-cell carcinoma and compare the results with those obtained using other screening modalities.
AuthorsS W Shelfo, M S Soloway
JournalWorld journal of urology (World J Urol) Vol. 15 Issue 2 Pg. 107-11 ( 1997) ISSN: 0724-4983 [Print] Germany
PMID9144900 (Publication Type: Journal Article, Review)
Chemical References
  • Biomarkers, Tumor
  • Nuclear Proteins
  • nuclear matrix protein 22
Topics
  • Biomarkers, Tumor (urine)
  • Carcinoma, Transitional Cell (diagnosis, urine)
  • Humans
  • Neoplasm Recurrence, Local
  • Nuclear Proteins (urine)
  • Urinary Bladder Neoplasms (diagnosis, urine)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: